The economic value of primary prophylaxis using pegfilgrastim compared with filgrastim in patients with breast cancer in the UK. (Q37607276)

21 August 2017

title

The economic value of primary prophylaxis using pegfilgrastim compared with filgrastim in patients with breast cancer in the UK. (English)

1 reference

21 August 2017

0 references

1 reference

Zhimei Liu

1

1 reference

21 August 2017

Quan V Doan

series ordinal

2

1 reference

21 August 2017

Jennifer Malin

series ordinal

3

1 reference

21 August 2017

Robert Leonard

series ordinal

4

1 reference

21 August 2017

publication date

1 January 2009

1 reference

Applied Health Economics and Health Policy

21 August 2017

published in

1 reference

21 August 2017

volume

7

1 reference

21 August 2017

issue

3

1 reference

21 August 2017

page(s)

193-205

1 reference

2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline

21 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FBF03256152

Reduction by Granulocyte Colony-Stimulating Factor of Fever and Neutropenia Induced by Chemotherapy in Patients with Small-Cell Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256152

Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256152

Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256152

A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256152

First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256152

EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256152

The impact of therapy with filgrastim (recombinant granulocyte colony-stimulating factor) on the health care costs associated with cancer chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256152

Comparison of pegfilgrastim with filgrastim on febrile neutropenia, grade IV neutropenia and bone pain: a meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256152

Are shorter courses of filgrastim prophylaxis associated with increased risk of hospitalization?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256152

When the risk of febrile neutropenia is 20%, prophylactic colony-stimulating factor use is clinically effective, but is it cost-effective?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256152

Relation between chemotherapy dose, oestrogen receptor expression, and body-mass index.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256152

30 years' follow up of randomised studies of adjuvant CMF in operable breast cancer: cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256152

Dose-response effect of adjuvant chemotherapy in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256152

Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin's lymphoma: a nationwide study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256152

Are prophylactic haematopoietic growth factors of value in the management of patients with aggressive non-Hodgkin's lymphoma?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256152

Cost-effectiveness of adding granulocyte colony-stimulating factor to primary prophylaxis with antibiotics in small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256152

The economics of the colony-stimulating factors in the prevention and treatment of febrile neutropenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256152

Incidence, cost, and mortality of neutropenia hospitalization associated with chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256152

Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256152

Impact of neutropenia on delivering planned adjuvant chemotherapy: UK audit of primary breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256152

Adjuvant docetaxel for node-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256152

Efficacy and cost-effectiveness of autologous bone marrow transplantation in metastatic breast cancer. Estimates using decision analysis while awaiting clinical trial results

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256152

Cost effectiveness of treatment options in advanced breast cancer in the UK.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256152

Cost-effectiveness of raloxifene and hormone replacement therapy in postmenopausal women: impact of breast cancer risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256152

The cost-effectiveness of routine postoperative radiotherapy after sector resection and axillary dissection for breast cancer stage I. Results from a randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256152

Risk models for predicting chemotherapy-induced neutropenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256152

Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256152

Effect of outpatient treatment of febrile neutropenia on the risk threshold for the use of CSF in patients with cancer treated with chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256152

Risk assessment in cancer patients with fever and neutropenia: a prospective, two-center validation of a prediction rule

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256152

Outpatient oral antibiotics for febrile neutropenic cancer patients using a score predictive for complications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256152

Outpatient treatment of low-risk neutropenic fever in cancer patients using oral moxifloxacin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256152

Early hospital discharge with oral antimicrobial therapy in patients with hematologic malignancies and low-risk febrile neutropenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256152

Recommendations of the Panel on Cost-effectiveness in Health and Medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256152

Use of quality adjusted life years and life years gained as benchmarks in economic evaluations: a critical appraisal

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256152

Effects of indirect and additional direct costs on the risk threshold for prophylaxis with colony-stimulating factors in patients at risk for severe neutropenia from cancer chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256152

Systematic overview of cost-utility assessments in oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256152

Evaluation of conflict of interest in economic analyses of new drugs used in oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256152

21 January 2018

Identifiers

DOI

10.1007/BF03256152

1 reference

21 August 2017

1 reference